Verici Dx publishes Circular and Notice of General Meeting

VRCI

Verici Dx Plc (LON:VRCI), a developer of advanced clinical diagnostics for organ transplant, has announced that a Circular has been published containing a notice of a general meeting to be held at the offices of Shoosmiths LLP at 1 Bow Churchyard, London, EC4M 9DQ at 11:30 a.m. on 22 June 2026.

The General Meeting is being held to ensure that the Company has sufficient authority to issue and allot new Ordinary Shares on a non-pre-emptive basis following the Fundraising announced on 5 June 2026.

The Circular and Notice of General Meeting has been posted to Shareholders and is available on the Company’s website at: https://vericidx.com/investors/documents/

Unless otherwise defined, all definitions used in this announcement will have the same meaning as described in the Circular.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Verici Dx publishes Circular and Notice of General Meeting

Verici Dx has published a circular convening a general meeting on 22 June 2026 to seek authority to issue new ordinary shares on a non-pre-emptive basis following its recent fundraising.

Verici Dx strengthens clinical case for kidney transplant risk testing

Verici Dx has strengthened the clinical evidence behind its pre-transplant kidney rejection risk test, supporting its investor case in precision transplant diagnostics.

Verici Dx launches ÂŁ200,000 WRAP Retail Offer

Verici Dx has opened a WRAP Retail Offer to raise up to ÂŁ200,000 through new ordinary shares priced at 0.35 pence each, alongside its recently announced ÂŁ2.5 million placing.

Verici Dx raises ÂŁ2.5m through placing

Verici Dx has completed a placing of 700 million shares at 0.35p each, raising gross proceeds of about ÂŁ2.5 million to support its organ transplant diagnostics business.

Verici Dx secures CPT PLA code for Protega and publishes PTRA study

Verici Dx has received a CPT PLA code for its Protega test and published analysis showing PTRA could deliver major U.S. healthcare savings in kidney transplant care.

Verici Dx takes aim at a persistent gap in kidney transplant care

Verici Dx is targeting a clear unmet need in kidney transplant care with molecular tests designed to improve rejection risk assessment and post-transplant monitoring.

Search